Advertisement

Dr. Heinemann on Using Depth of Response in Pretreated Patients With CRC

Published on: 

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses using depth of response as an appropriate endpoint in studies examining patients with metastatic colorectal cancer (mCRC).

Advertisement

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses using depth of response as an appropriate endpoint in studies examining patients with metastatic colorectal cancer (mCRC).

Depth of response is an important endpoint to measure when investigating triplet chemotherapy regimens, such as FOLFOXIRI, or the addition of an EGFR-targeted agent to a doublet-chemotherapy regimen in ROS1-positive patients, Heinemann explains.

It is here that depth of response, as well as tumor shrinkage, can be associated with overall survival, Heinmann says.


Advertisement
Advertisement